Progress and challenges in measles and rubella elimination in the WHO European Region. Issue 36 (28th August 2018)

• Record Type: Journal Article
• Authors: Datta, Siddhartha Sankar; O'Connor, Patrick Michael; Jankovic, Dragan; Muscat, Mark; Ben Mamou, Myriam Corrine; Singh, Simarjit; Kaloumenos, Theodoros; Reef, Susan; Papania, Mark; Butler, Robb
• Is Part Of: Vaccine. Volume 36:Issue 36(2018)
• Page Start: 5408
• Page End: 5415
• Publication Date: 2018-08-28
• Subjects: Disease elimination -- European Region -- Measles -- Rubella -- Progress -- Verification -- Vaccines; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.06.042
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: By 2015, over half of the 53 countries interrupted endemic transmission of measles and rubella. Measles and rubella cases have declined, as has the number of measles genotypes. All countries in the Region are committed to the goal of eliminating measles and rubella. Several challenges in vaccination and surveillance performance still remain. Critical programmatic issues need to be addressed to achieve regional elimination. Abstract: Introduction: Despite availability of safe and cost-effective vaccines to prevent it, measles remains one of the significant causes of death among children under five years of age globally. The World Health Organization (WHO) European Region has seen a drastic decline in measles and rubella cases in recent years, and a few of the once common measles genotypes are no longer detected. Buoyed by this success, all Member States of the Region reconfirmed their commitment in 2010 to eliminating measles and rubella, and made this a central objective of the European Vaccine Action Plan 2015–2020 (EVAP). Nevertheless, sporadic outbreaks continue, recently affecting primarily adolescents and young adults with no vaccination or an incomplete vaccination history. The European Regional Verification Commission for Measles and Rubella Elimination was established in 2011 to evaluate the status of measles and rubella elimination based on documentation submitted annually by each country's national verification committee. Discussion: Each country's commitment to eliminate measles and rubella is influenced by competing health priorities, and in some cases lack of capacity and resources. All countries need to improve case-base surveillance for both measles and rubella, ensure documentation of each outbreak and strengthen the link between epidemiology and laboratory data. Achieving high coverage with measles- and rubella-containing vaccines will require a multisectoral approach to address the root causes of lower uptake in identified communities including service delivery challenges or vaccine safety concerns caused by circulating myths about vaccination. Conclusions: The WHO European Region has made steady progress towards eliminating measles and rubella and over half of the countries interrupted endemic transmission of both diseases by 2015. The programmatic challenges in disease surveillance, vaccination service delivery and communication in the remaining endemic countries should be addressed through periodic evaluation of the strategies by all stakeholders and exploring additional opportunities to accelerate the ongoing elimination activities.